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Abstract
Purpose In peptide receptor radionuclide therapy (PRRT), the
bone marrow (BM) is one of the dose-limiting organs. The
accepted dose limit for BM is 2 Gy, adopted from 131I treat-
ment. We investigated the incidence and duration of haemato-
logical toxicity and its risk factors in patients treatedwith PRRT
with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE). Also,
absorbed BM dose estimates were evaluated and compared
with the accepted 2 Gy dose limit.
Methods The incidence and duration of grade 3 or 4 haema-
tological toxicity (according to CTCAE v3.0) and risk factors
were analysed. Mean BM dose per unit (gigabecquerels) of
administered radioactivity was calculated and the correlations
between doses to the BM and haematological risk factors were
determined.
Results Haematological toxicity (grade 3/4) occurred in 34
(11 %) of 320 patients. In 15 of the 34 patients, this lasted
more than 6 months or blood transfusions were required. Risk
factors significantly associated with haematological toxicity
were: poor renal function, white blood cell (WBC) count
<4.0×109/l, age over 70 years, extensive tumour mass and
high tumour uptake on the OctreoScan. Previous chemother-
apy was not associated. The mean BM dose per administered
activity in 23 evaluable patients was 67±7 mGy/GBq,
resulting in a mean BM dose of 2 Gy in patients who received
four cycles of 7.4 GBq 177Lu-DOTATATE. Significant corre-
lations between (cumulative) BM dose and platelet and WBC
counts were found in a selected group of patients.
Conclusion The incidence of subacute haematological toxic-
ity after PRRT with 177Lu-DOTATATE is acceptable (11 %).
Patients with impaired renal function, lowWBC count, exten-
sive tumour mass, high tumour uptake on the OctreoScan and/
or advanced age are more likely to develop grade 3/4 haema-
tological toxicity. The BM dose limit of 2 Gy, adopted from
131I, seems not to be valid for PRRTwith 177Lu-DOTATATE.
Keywords PRRT . 177Lu-DOTATATE . Bonemarrow .
Toxicity . Dosimetry
Introduction
In the past two decades, peptide receptor radionuclide therapy
(PRRT) with radiolabelled somatostatin analogues has been
used successfully in patients with somatostatin receptor-
positive tumours. One of the most frequently used radiophar-
maceuticals is 177Lu-DOTA0-Tyr3-octreotate (177Lu-
DOTATATE). Patients with neuroendocrine tumours treated
with 177Lu-DOTATATE have a radiological response rate of
15 – 35 % [1–5]. Generally, PRRT is well tolerated, but the
kidneys and bone marrow (BM) are usually the dose-limiting
organs.
BM toxicity results from irradiation of and damage to
haematopoietic tissue. Grade 3 or 4 haematological toxicity
develops in about 5 – 10 % of patients [6–11]. The nadir
normally occurs 4 – 6 weeks after each treatment, followed
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by a recovery phase. The generally accepted threshold dose
for radiation-induced BM suppression is 2 Gy, adopted from
131I therapy studies [12, 13]. However, up to now, no data
have been published that confirm or reject this BM dose limit
for 177Lu-DOTATATE.
The aim of this study was to analyse short-term haemato-
logical toxicity after PRRTwith 177Lu-DOTATATE. Risk fac-
tors analysed included renal function, chemotherapy, baseline
cytopenia, tumour mass and patient age. In addition, the indi-
vidual and mean BM doses were calculated in a subgroup of
patients.
Materials and methods
Patients
The study included 320 Dutch patients who were treated from
January 2000 to December 2007. Inclusion criteria were: pa-
tients with neuroendocrine tumour and baseline tumour up-
take on [111In-DTPA0] octreotide scintigraphy (OctreoScan®;
Mallinckrodt, Petten, The Netherlands) with accumulation in
the tumour at least as high as in normal liver tissue; no prior
treatment with PRRT; baseline serum haemoglobin (Hb)
≥6 mmol/l; white blood cell (WBC) count ≥2×109/l; platelet
(PLT) count ≥75×109/l; serum creatinine ≤150 µmol/l or cre-
atinine clearance ≥40 ml/min and Karnofsky performance sta-
tus ≥50. Only Dutch patients were selected, because loss to
follow-up is limited in these patients.
This study was part of the ongoing prospective study in
patients with neuroendocrine tumours treated with 177Lu-
octreotate at the Department of Nuclear Medicine, Erasmus
University Medical Center Rotterdam. The hospital’s medical
ethics committee approved the study. All patients gave written
informed consent for participation in the study.
Treatment
[DOTA0,Tyr3] octreotate was obtained from BioSynthema
(St. Louis, MO). 177LuCl3 was supplied by IDB-Holland
(Baarle-Nassau, The Netherlands) and 177Lu-DOTATATE
was prepared locally [14].
Granisetron 3 mg or ondansetron 8 mg was injected intra-
venously 30 min before infusion of 177Lu-DOTATATE. Infu-
sion of amino acids (2.5 % arginine and 2.5 % lysine, 1 l) was
started 30 min before administration of the radiopharmaceuti-
cal and lasted for 4 h. The radiopharmaceutical was
coadministered for 30 min using a second pump system. Cy-
cle dosages of 1.85 GBq (50 mCi) were given in 4 patients,
3.7 GBq (100 mCi) in 13 patients, 5.6 GBq (150 mCi) in 14
patients, and 7.4 GBq (200 mCi) in the remaining patients,
injected over 30 min. The interval between treatments was
6 – 16 weeks. The intended cumulative dose was 29.6 GBq
(800 mCi). Median cumulative activity was 29.6 GBq, range
7.4 – 29.6 GBq. However, the dose was lowered if the calcu-
lated kidney dose was higher than 23 Gy. Other reasons for
dose reduction or cessation of further therapy were recurrent
grade 3 or 4 haematological toxicity and persistent low blood
counts.
Dosimetry
Biodistribution and dosimetry studies were performed in three
subgroups of patients. The data on estimated BM doses have
been published previously [14–16]. Only patients meeting the
inclusion criteria, as stated above, and with complete datasets
for dosimetry were included in the present analysis. The BM
dose (Drm) is derived from three sources: (1) from the blood
circulating through the marrow cavities (rm), (2) from large
organs and tumours with high radioactivity uptake (h), and (3)
from the general distribution of radioactivity throughout the
remaining whole body (rb):
Drm ¼ ~ArmDF rm←rmð Þ þ ~AhDF rm←hð Þ þ ~ArbDF rm←rbð Þ
where Ã is the cumulative activity and DF are the dose factors
for red marrow to red marrow, large organs to red marrow, and
remainder of the body to red marrow. The contribution to the
BM dose from radioactivity distribution within the remainder
was calculated (and corrected) according to the method of
Wessels et al. [17].
Calculated dose contributions were based on planar scans
(at 24, 96 and 168 h after injection), and radioactivity mea-
sured in urine (at 1, 6, 24, 48 h after injection) and blood
samples (at 0, 10, 30, 60, 90, 120, 360 and 1,440 min after
injection). A pharmacokinetics (PK) compartment model was
used to describe the biodistribution of radioactivity in organs
over time. Organs with physiological uptake (kidneys and
abdomen) were added to the central (blood) compartment
(Fig. 1). A single compartment linked to the kidney was able
to model the urine data. An additional remainder-of-the-body
compartment was used to fit the data. Flow in both directions
between compartments was modelled by kinetic transfer com-
ponents, k(i,j). The PK compartment model was numerically
solved using SAAMII software (Simulation Analysis and
Modeling; SAAM Institute, Seattle, WA). BM dose values
were computed using the Olinda/EXM software package
(Vanderbilt University) and using dose factors for 177Lu [18].
Toxicity assessment
Haematology, and liver and renal function tests were per-
formed during the 6 weeks before the first therapy, 4 and
6 weeks after each therapy, and at follow-up visits. Haemato-
logical toxicity was assessed according to Common Terminol-
ogy Criteria for Adverse Events (CTCAE v3.0) [19]. This
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version of CTCAE was used because of well-defined criteria
for thrombocytopenia, leucocytopenia and anaemia. Haema-
tological toxicity was modelled for toxicity grade 3/4 in PLT
count, WBC count, Hb and a combination of all three. The
duration of grade 3/4 haematological toxicity was defined as
the time from the last therapy until recovery to toxicity grade 2
or lower.
Statistical analysis and parameters
SPSS software (SPSS 19; IBM, New York, NY) was used for
statistical analysis. Distributions were examined for normality
using the Kolmogorov-Smirnov test. Correlations between
distributions were evaluated using the χ2 test, t test and anal-
ysis of variance. Spearman’s rank correlation coefficient was
used for correlation analysis. Regression analysis was per-
formed with the binary logistic model. Conditional step-
forward and step-backward methods were used with the fol-
lowing parameters: classification cut-off 0.5, maximum itera-
tions 20, probability for entry 0.05 and removal 0.20. P values
<0.05 (for both step-forward and step-backward) were consid-
ered significant. The following discrete baseline variables
were included in the analysis: gender, age over 70 years, pres-
ence of bone metastasis, prior chemotherapy, prior external
beam radiotherapy, uptake on the OctreoScan, tumour load,
chromogranin A >2,000 μg/l, splenectomy, baseline PLT
count <150×109/l and baseline WBC count <4.0×109/l. The
creatinine clearance was estimated with the Cockcroft-Gault
formula and evaluated as a continuous variable. Similar re-
gression analyses were performed setting thresholds for de-
creases in PLT count, WBC count and Hb of 15 % and 25 %
after the first therapy. Univariate analysis was performed in a
subgroup of patients with transient and persistent grade 3/4
haematological toxicity.
In the dosimetric subgroups, the correlations between the
percentage reductions in blood cells (Hb, PLT count, WBC
count) after the first therapy and dose to the BM were
determined using Spearman’s rank correlation coeffi-
cients (rS). The median and mean doses to the BM per
unit (gigabecquerels) of administered radioactivity were
calculated for each subgroup separately and for all three
subgroups combined.
Results
In total, 324 patients were evaluated. The patient char-
acteristics are summarized in Table 1. Four patients
were excluded because of unrelated haematological tox-
icity (internal bleeding in three and iron-deficiency
anaemia in one).
Fig. 1 Generalized compartment model for the biodistribution of 177Lu-
DOTATATE in humans. Compartments (C1 to C5) represent different
organs. Flow in both directions between compartments is represented
by kinetic transfer components, k(i,j). The shaded grey circles represent
input (radioactivity) data and the open grey circle represents modelled
output. Injection is a simulated bolus of 177Lu-DOTATATE in the blood
compartment
Table 1 Baseline characteristics of 320 Dutch patients
Characteristic Number of patients (%)
Male 164 (51)
Age ≥70 years 62 (19)
Karnofsky performance status ≤70 46 (14)
Elevated chromogranin A 237 (74)
Bone metastasis 72 (23)
Splenectomy 12 (4)
WBC count <4.0×109/l at baseline PRRT 16 (5)
Previous therapy
Chemotherapy 38 (12)
Radiotherapy (external) 32 (10)
Tumour type
Neuroendocrine 278 (87)
Other 42 (13)
Tumour uptake on baseline OctreoScan
Equal to or more than normal liver 248 (77)
Higher than kidneys 72 (23)
Tumour mass on baseline OctreoScan
Equal to or more than normal liver 264 (82)
Higher than kidneys 56 (18)
Cumulative activity (GBq)
≤22.2 103 (32)
≤29.6 215 (67)
Kidney function, mean (range) creatinine
clearance in millilitres per minute,
Cockcroft-Gault
99 (35 – 246)
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Toxicity
Severe subacute haematological toxicity (grade 3/4) occurred
4 to 8 weeks after administration in 34 (11 %) of the 320
patients, with thrombocytopenia in 25 (8 %), leucocytopenia
in 17 (5 %), anaemia in 10 (3 %) and pancytopenia (1 %)
(Fig. 2).
Two patients were excluded from the analyses for toxicity
duration. One patient (with grade 4 thrombocytopenia) died
6 weeks after last the treatment due to bowel obstruction, and
one patient (with grade 3 thrombocytopenia and grade 3 anae-
mia) died 9 weeks after last the treatment due to progressive
disease. Of 30 patients, 15 (50 %) had grade 3/4 haematolog-
ical toxicity lasting more than 6 months or required blood
transfusion. The duration of haematological toxicity in these
patients is presented in Fig. 3.
Baseline parameters that were significantly associated with
grade 3/4 haematological toxicity were: decreased renal func-
tion, WBC <4.0×109/l, age >70 years, extensive tumour
mass, and tumour uptake on the OctreoScan more than uptake
in the kidneys (Table 2). No significant association was found
for previous chemotherapy.
Of 30 patients with persistent (more than 6 months) hae-
matological toxicity or who required blood transfusions, 15
had significantly more tumour mass on the baseline
OctreoScan than patients with transient (6 months or less)
grade 3/4 haematological toxicity. No significant difference
in other baseline variables was found between these two sub-
groups (data not shown). In patients with decrease in Hb of
more than 15 % after the first therapy, previous radiotherapy
was an additional significant factor in the logistic regression
analysis (p=0.005 and p=0.001 for step-forward and step-
backward methods, respectively). In patients with a decrease
in Hb, PLT count and/or WBC count of more than 25 % after
the first therapy, decreased renal function at baseline was the
only significant variable (p<0.05).
Dosimetry
The dosimetry analysis included 32 patients split into three
groups with different cycle doses (1.85, 3.7 and 7.3 GBq
177Lu-DOTATATE). Of the 32 patients, 25 patients were treat-
ed according protocol; in two patients no complete dosimetric
data were available. The BM dose after the first therapy was
determined in 25 patients: 4 patients in group 1 (cycle dose
1.85 GBq), 7 patients in group 2 (cycle dose 3.7 GBq) and 14
patients in group 3 (cycle dose 7.3 GBq). The cumulative dose
was 14.8 GBq in 1 patient, 22.2 GBq in 9 patients and
29.6 GBq in 15 patients. The median dose (and range) to the
BM per unit of administered radioactivity in patients in group
1 and group 2 was 69 mGy/GBq (54 – 73 mGy/GBq) and
75 mGy/GBq (35 – 139 mGy/GBq), respectively. In group 3
the median dose (and range) was 51 mGy/GBq
(24 – 116 mGy/GBq) excluding one outlier of 331 mGy/
GBq. In this patient the urinary excretion data could not be
fitted correctly in the compartment model. This resulted in a
long residence time of activity in the total body and in an
exceptionally high BM dose, leading to the exclusion of this
patient from further analysis (Supplementary Data). Despite a
high calculated BM dose, this patient did not develop grade 3
or 4 haematological toxicity.
Data from groups 1, 2 and 3 combined were normally dis-
tributed (Kolmogorov-Smirnov test) allowing calculation of
the mean BM dose. The mean BM dose (excluding one out-
lier) per unit of administered activity in the 24 evaluable pa-
tients was 0.067±0.007 mGy/MBq. At an activity administra-
tion schedule of 4×7.4 GBq (which most patients received)
this would lead to a BM dose of 2.0±0.2 mGy. Three (13 %)
of 23 patients developed grade 3/4 haematological toxicity.
No significant difference in BM dose was observed between
these 3 patients and the other 20. Significant Spearman’s rank
correlation coefficients and P values (one-tailed) were found
in group 3 between (cumulative) BM dose and PLTcount after
the first and last treatments (rS=−0.51 with P<0.05 and rS=
−0.59 with P=0.02, respectively) and WBC count (rS=−0.70
with P=0.01 and rS=−0.51 with P<0.05, respectively;
Fig. 4). No significant correlation between (cumulative) BM
dose and haemoglobin was found in group 3, and no signifi-
cant correlations were found between (cumulative) BM dose
and blood cells in group 1 and group 2.
Discussion
Subacute haematological grade 3/4 toxicity was observed in
34 (11%) of 320 patients receiving 177Lu-DOTATATE. In half
of these patients, toxicity persisted for more than 6 months or
blood transfusions were required. This is in accordance with
data from other groups [5–10]. Long-term haematological tox-
icities, such as myelodysplastic syndrome (MDS) and acute
Fig. 2 Venn diagram of haematological toxicity (grade 3/4) in 34 out of
320 patients treated with a median cumulative dose of 29.6 GBq 177Lu-
DOTATATE
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leukaemia (AL), have been found in patients receiving PRRT
with 177Lu-DOTATATE [6, 11]. Also in our patient group,
MDS and AL were observed, but since these events have a
rare complex stochastic character, they will be reported in a
separate study. In a recent study, long-term side effects of
PRRTwith 90Y-octreotide and/or 177Lu-octreotate were inves-
tigated [6]. The authors found more haematological toxicity
after PRRT in patients with baseline nephrotoxicity (transient
or persistent elevation in creatinine). The prolonged circula-
tion time of 177Lu-DOTATATE in patients with a poor renal
function is probably the most important factor that explains
the increased toxicity to the BM, as shown by Svensson et al.
[20]. Also anaemia is common in these patients due to a re-
duction in renal erythropoietin production. In our study, poor
renal function was also found to be a predictor of haematolog-
ical toxicity.We also found that a low baselineWBC count is a
predictor of grade 3/4 haematological toxicity. This is in line
with the findings of a recent study showing that baseline cy-
topenia is a predictor of haematological toxicity after PRRT
[9].
From a dosimetric point of view, it has been theorized that
patients with a large tumour burden and high receptor density
have lower amounts of circulating activity [21]. Therefore the
radiation to normal tissues could be less than in patients with a
low tumour burden. However, in our study, patients with more
tumour mass at baseline were significantly more likely to have
grade 3/4 haematological toxicity. Furthermore, high tumour
burden was more frequently found in patients with persistent
grade 3/4 haematological or who required blood transfusion.
This suggests that tumour burden plays a role in the develop-
ment and duration of haematological toxicity, in contrast to the
recently described tumour sink effect [22]. That study showed
that internalization of 68Ga-DOTATATE in the tumour leads to
a significant decrease in uptake in healthy tissue, the so-called
tumour sink effect [22]. The authors extrapolated their results
and speculated on a similar effect for PRRT. However, the
main contributing factor for radiation dose to an organ (i.e.
the BM) from PRRT is the exposure to radiation over time and
the organ dose cannot be based on a distribution with only one
time point. In our limited subgroup of patients in whom
biodistribution and dosimetry data were available, we were
not able to demonstrate the tumour sink effect.
Past chemotherapy was not a clear risk factor in our anal-
yses. This finding can be explained by the limited number of
patients who received chemotherapy in our series (38 of 320
patients, 12 %). In other studies more than 25 % of patients
have had a history of chemotherapy [6, 8, 9]. In particular,
chemotherapy regimens with alkylating agents (e.g. cisplatin,
carboplatin, oxaliplatin) or topoisomerase II inhibitors (e.g.
etoposide) can damage the DNA of haematopoietic cells
Fig. 3 Duration of subacute
haematological toxicity (grade
3/4) in 32 of 320 patients treated
with a median cumulative dose of
29.6 GBq 177Lu-DOTATATE: a
any toxicity in 32 patients, b
thrombocytopenia in 23 patients,
c leucocytopenia in 17 patients,
and d anaemia in 9 patients
(NA results not available during
follow-up, Transfusion patients
who received blood cell
transfusion after grade 3/4
haematological toxicity. Two
patients were excluded (see text)
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[23]. A small number (12 %) of patients in our study had
received this type of chemotherapy in the past, therefore lim-
iting the statistical power of this (possible) risk factor.
A potential protective effect of splenectomy on the devel-
opment of haematological toxicity in patients receiving 177Lu-
DOTATATE has recently been reported [9]. The spleen is a
major reservoir of blood cells and uptake of radioactivity is
mainly caused by the presence of somatostatin receptors on
lymphocytes [14, 24]. Blood cells circulating throughout the
spleen may be damaged leading to a reduction in peripheral
blood cell counts. However, in another clinical study with
177Lu-DOTATATE/DOTATOC, no correlation was found be-
tween dose to the spleen and haematological toxicity during
PRRT [25]. In our study, none of the 12 patients who had had
a splenectomy developed grade 3/4 haematological toxicity.
This supports the idea that splenectomy has a protective effect
in patients receiving PRRT, but statistical analysis could not
be performed due to the limited number of patients with
splenectomy.
PRRT using 177Lu-DOTATATE shows similarities to 131I
treatment, because of the comparable half-life (6.7 and
8.0 days, respectively) and similar energies of the emitted β
radiation (with average energies of 133 and 182 keV, respec-
tively). Therefore in 2000, we accepted a maximum BM dose
for PRRT with 177Lu-DOTATATE, which was adopted from
clinical studies with 131I treatments. The upper BM dose limit
was set to 2 Gy, based on early work in thyroid cancer patients
treated with 131I [12]. In that study, 122 doses of 131I were
administered to 59 patients with metastasized thyroid cancer.
In 14 administrations of 131I, serious radiation complications
were observed (Table 3, original table). The authors stated that
serious radiation complications per treatment cycle were more
frequent when the total dose to the blood exceeded 200 rad
(2Gy) with a significance ofP=0.03 (Table 3). However, only
8 of 14 serious radiation complications were related to the
BM; the other complications were pneumonitis or vomiting.
When we repeated the analysis, taking into account only seri-
ous BM complications (Table 3, modified table), no signifi-
cantly higher frequency of haematological toxicity for BM
radiation doses more than 2 Gy could be demonstrated (Fish-
er’s exact test, P=0.68). Also, all eight patients with radiation
complications (related to the BM) hadmetastatic disease to the
bone. Bone metastases are a source of radiation after PRRT
and could contribute to an increase in BM dose. However, in
Table 2 Baseline clinical
parameters associated with grade
3/4 haematological toxicity in 34
of 320 patients treated with a
median cumulative dose of
29.6 GBq 177Lu-DOTATATE
from logistic regression analysis
with the stepwise method (step-
forward and step-backward)
Variable Step-forward Step-backward
Coefficientb p value Coefficientb p value
Any toxicity (Hb/PLT/WBC)
Creatinine clearance (Cockcroft-Gault)a −0.160 0.028 −0.150 0.044
Bone metastasis 1.055 0.017 0.912 0.056
WBC count <4.0×109/l at baselinea 1.828 0.005 1.741 0.011
Tumour uptake on Octreoscan> kidney uptake 0.867 0.051 1.055 0.023
Previous radiotherapy Not in predictive equation 1.225 0.074
Previous chemotherapy Not in predictive equation 1.171 0.161
Haemoglobin
Age >70 yearsa 1.698 0.045 1.860 0.039
Extensive tumour massa 2.551 0.002 2.570 0.003
Previous radiotherapy Not in predictive equation 2.165 0.036
Platelets
Creatinine clearance (Cockcroft-Gault)a −0.022 0.010 −0.025 0.008
Bone metastasis 1.268 0.009
WBC count <4.0×109/l at baseline 1.731 0.016 1.565 0.196
Extensive tumour mass Not in predictive equation 1.174 0.024
Previous radiotherapy Not in predictive equation 1.392 0.055
Previous chemotherapy Not in predictive equation −1.604 0.144
White blood cells
Age >70 years Not in predictive equation 1.161 0.062
WBC count <4.0×109/l at baselinea 2.436 0.001 2.531 0.000
Tumour uptake on Octreoscan> kidney uptakea 1.321 0.022 1.549 0.010
Previous radiotherapy 1.363 0.068 Not in predictive equation
a Variable statistically significant (p<0.05) in multivariate analyses
b Logistic coefficient in predictive equation
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our multivariate analysis, the presence of bone metastases was
not a risk factor for developing grade 3/4 haematological
toxicity.
Another comment on the study by Benua et al. is that the
radiation complications per unit administered dose were
analysed and the cumulative BM dose per patient was not
considered. This resulted in a double count of radiation com-
plications in one patient (after the first and second dose of
131I). In our study, haematological toxicity was counted only
once per patient since the chance of recurrent haematological
toxicity in one patient is relatively high. We also analysed the
cumulative BM dose instead of complications per administra-
tion, considering that multiple sequential treatments reduce
the BM reserve. In a more recent article, the BM limit was
set to 3 Gy for 131I treatment, based on 104 treatments in 83
thyroid cancer patients [26]. No permanent BM suppression
was observed, but two patients required PLT and red blood
cell transfusion because of pancytopenia.
In the past decade, several studies with BM dose estimates
using 177Lu-DOTATATE have been reported (Table 4). Vari-
ations in the reported BM dose estimates can partly be attrib-
uted to differences in accuracy of dosimetric methods [27]. In
a recent Swedish study, 200 patients who were treated with
7.4 GBq 177Lu-DOTATATE were analysed and BM doses
were calculated based on blood-based and organ-based anal-
ysis of the whole-body images. The authors calculated a
Fig. 4 Platelet counts (a, b),
white blood cell counts (c, d) and
haemoglobin (e, f) expressed as
percentages of the baseline values
in relation to bonemarrow dose in
23 patients after the first and last
treatments with 177Lu-
DOTATATE (circles group-1,
1.85 GBq, n=4; squares group 2,
3.70 GBq, n=7; triangles group
3, 7.40 GBq, n=12). Solid lines is
linear regression with 95 %
confidence intervals (dotted
lines). Significant Spearman’s
rank correlation coefficients with
(one-tailed) P values in group 3: a
rS=−0.51 with P<0.05, b rS=
−0.59 with P=0.02, c rS=−0.70
with P=0.01, d rS=−0.51 with
P<0.05
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maximum BM dose of 0.4 Gy per cycle of 7.4 GBq, which
would result in a cumulative BM dose of 1.6 Gy for four
cycles. Our data showed an estimated mean BM dose of
2.0 Gy (SD 0.2 Gy) in 184 out of 320 patients who received
four cycles of 7.4 GBq 177Lu-DOTATATE. Therefore, half of
these patients (92 of 184) received a BM dose of more than
2 Gy. If the true maximum tolerated dose to the BM were
2 Gy, these 92 patients would theoretically be more prone to
develop haematological toxicity. However, we found haema-
tological toxicity in only 34 of the 320 patients. This supports
the idea that a higher BM dose limit for PRRT with 177Lu-
DOTATATE is appropriate. Another argument for a different
BM dose maximum is the success of retreatment with extra
cycles of PRRT without serious haematological side effects
[28]. In our analysis of this type of retreatment, in which
selected patients received a cumulative BM dose of approxi-
mately 3 Gy, only 5 (16 %) of 32 patients developed grade 3/4
haematological toxicity after two additional cycles of 177Lu-
DOTATATE. In another study reversible haematotoxicity
(grade 3/4) was found in 7 (21.2 %) of 33 patients who
underwent salvage PRRT [29]. In our ongoing study in Eras-
mus MC, we have treated a selected group of patients with
multiple additional cycles of 177Lu-DOTATATE with cumula-
tive doses up to 59.2 GBq resulting in an estimated mean BM
dose of more than 3 Gy with limited haematological toxicity
(unpublished data).
Several groups have investigated the role of BM dosimetry
in radionuclide treatments for predicting haematological tox-
icity. Aweak negative correlation (rp=−0.47) between neutro-
phils at nadir and measured whole-body absorbed dose was
Table 3 Complications in
relation to total BM radiation dose
reported by Benua et al. [12], and
with new modifications. Data
were derived from patients treated
with radioiodine 131I treatment
Blood total
radiation (Gy)
No. of
doses
Original tablea Modified tableb
Radiation complications BM radiation complications
Severe Fatal Total in
percent
Severe Fatal Total in
percent
0 – 0.99 5 0 0 0 0 0 0
1.00 – 1.99c 24 1 0 4 1 0 4
2.00 – 2.99 33 5 1 18 3 1 12
3.00 – 3.99 7 1 1 29 1 0 14
4.00 – 4.99 9 0 2 22 0 1 11
Over 5.00 7 2 0 29 1 0 14
Unknown 37 1 0 3 0 0 0
Total 122 10 4 7 6 2 7
aOriginal table of Benua et al. [12]
bModified table with only serious bone marrow radiation complications
c Significantly more frequent complications with total dose >200 rad are stated in the original table, but are not
significant in the modified table
Table 4 Overview of reported data on BM dosimetry for PRRTwith 177Lu-DOTATATE
Reference Number of
patients
Dosimetric
method
Administered
activity (GBq)
Amino acids BM dose
Per unit administered
activity (Gy/GBq)
For four cycles
of 7.4 GBq (Gy)
14 5 Planar 1.85 Lys/Arg 0.070±0.009 2.1
36 69 Planar 3 – 7 Lys/Arg 0.050±0.020 1.5
16 13 Planar 7.47 Lys/Arg 0.01 – 0.13 0.30 – 3.85
4 16 SPECT/CT 7.4 Vamin 14 0.070±0.020 2.1
2 12 Not reported 3.7 – 7.4 Lys 0.002 – 0.060 0.6 – 1.8
37 200 SPECT/CT 7.4 Vamin 14 0.006 – 0.050 0.2 – 1.5
This study 25a Planar 1.85 – 7.3 Lys/Arg 0.067±0.007 2.0
Lys/Arg lysine 2.5 %/arginine 2.5 %, Lys lysine 2.5 %
aOf 320 patients
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found in 20 patients treated with 131I-MIBG [30]. In a PRRT
study with 90Y-DOTATOC, a correlation (R=0.58) was found
between BM absorbed dose and PLT count reduction at nadir
[31, 32]. BM dose was calculated in 12 patients based on
plasma samples, assuming that the activity concentration in
the BM was equal to that in the plasma. 86Y-DOTATOC PET
was performed after therapy and showed uptake in the verte-
brae. Taking the radioactivity in the spine into the dosimetric
calculations, a better correlation (R=0.82) was found between
BM absorbed dose and PLT count reduction at nadir. Howev-
er, 24 patients did not demonstrate sufficient uptake of 86Y-
DOTATOC in the spine to provide usable BM dose measure-
ments. In our study, we found similar correlation coefficients
between the relative decrease in blood cells and (cumulative)
radiation dose to the BM. We found no correlation between
BM dose and Hb, which can be explained by minimal effects
on circulating erythrocytes after 2 Gy of irradiation [33].
These weak correlations between decreases in blood count
and BM dose indicate that current dosimetry cannot fully pre-
dict haematological toxicity. Additional clinical factors have
to be taken into account to predict haematological toxicity in
PRRT.
Further research should focus on reporting BM dose in
patients receiving PRRT with 177Lu-DOTATATE. BM dose
limits should be explored at the population level with clinical
toxicity grading (e.g. CTCAE) as outcome. However, current
BM dosimetry is imprecise and varies due to differences in
method of BM dose calculation [34]. Also the absorbed BM
dose does not reflect the damage done to the haematopoietic
stem cell department. If BM dosimetry can reflect the actual
dose to haematopoietic stem cells, it will have a more prom-
inent place in clinical practice during PRRT. In vivo markers
might also be an option for assessment of BM status after
irradiation with PRRT. In a recent article, γ-H2AX foci in
lymphocytes were successfully used for monitoring ionizing
radiation-induced DNA double-strand breaks in patients treat-
ed with 177Lu-DOTATATE [35]. However, the response of γ-
H2AX foci varied significantly between patients over time,
making it less suitable for individual monitoring. In future,
BM radiation dose could provide information for decision-
making in a clinical setting, but at present BM dosimetry plays
a minor role in clinical practice. Clinical parameters and blood
cell count recovery are currently the most important criteria
for individual PRRT planning.
Conclusion
The prevalence of subacute haematological toxicity (grade 3
or 4) after PRRT with 177Lu-DOTATATE is low (11 %). Our
dosimetric calculations of the absorbed BM dose support the
idea that a BM dose limit of more than 2 Gy seems appropriate
for PRRT with 177Lu-DOTATATE. A correlation was found
between BM dose and decreases in blood counts, but clinical
risk factors are currently the most important parameters for
prediction of clinical toxicity. Patients with impaired renal
function, low WBC count, extensive tumour mass, high tu-
mour uptake on the OctreoScan and/or those of advanced age
are more likely to develop grade 3 or 4 haematological toxic-
ity. Our data support the idea that a higher BM dose limit of
2 Gy is appropriate for PRRTwith 177Lu-DOTATATE.
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